Latest News for: cb1

Edit

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for ...

Nasdaq Globe Newswire 11 Dec 2025
CRB-913 is a highly peripherally restricted oral small molecule CB1 inverse agonist targeting chronic ...
Edit

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (Form 8-K) (Corbus Pharmaceuticals Holdings Inc)

Public Technologies 11 Dec 2025
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 ... CRB-913 is a highly peripherally restricted oral small molecule CB1 inverse agonist targeting chronic obesity management.
Edit

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913�for ...

Nasdaq Globe Newswire 10 Dec 2025
Company will host conference call and live webcast to review and discuss the data at 8.00 am ET. Company will host conference call and live webcast to review and discuss the data at 8.00 am ET ... .
Edit

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 (Corbus Pharmaceuticals Holdings Inc)

Public Technologies 10 Dec 2025
) Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 ... (GPCR) cannabinoid type-1 (CB1).
Edit

How Broncos have an elite CB1 despite losing Patrick Surtain II to injury

Sportingnews 28 Oct 2025
As ESPN analyst Ben Solak pointed out, Riley Moss, the Broncos' normal number two cornerback, is playing at CB1 levels this season.Why Broncos still have a No.1 CB with Patrick Surtain II out.
Edit

New obesity drug boosts GLP-1 weight loss without added side effects

New Atlas 12 Oct 2025
I believe these results warrant further evaluation of the therapeutic potential of this novel CB1 inhibitor.” ... The CB1 receptor is part of the body’s endocannabinoid system, which regulates appetite, metabolism, and fat storage.
Edit

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for ...

Nasdaq Globe Newswire 19 Sep 2025
Novel CB1 inhibitor Phase 1b data highlights lack of ...
  • 1

Article Search

tools
×
×
×
×